Our company social responsibility

As well as our dedication to improving the lives of patients, Ipsen is also firmly committed to protecting the environment and supporting civil society and the communities in which we operate. The group is pledged to promote ethical, responsible and transparent professional practices.

Ethics & compliance

Ethics & compliance

Our bold and entrepreneurial spirit combined with the highest ethical standards constitutes the heart of our organisation. This is the foundation of our approach to listen, partner and work with all of our stakeholders.
Our dedication to improve the health and quality of life of our patients demands the uppermost ethical standards throughout all areas of company life, from research and development through to marketing.  We ensure that all decisions are made independently, in the best interests of patients and in compliance with all applicable laws, regulations, industry codes, Ipsen policies and the Ipsen Code of Conduct. We strive to instil understanding of our values & to empower people to make decisions in light of these values, and in the best interest of patients.

Ethics & compliance

Our vision is to harness the power of our employees to have a responsible and sustainable impact on patients, society and the environment.

People

Caring for and developing employees, encouraging diversity and inclusion, and supporting an open and respectful culture

Patient & Society 

Providing innovative solutions for the benefit of patients & society based on trusted ​relationships and shared commitments

Environment 

​Protecting the environment, minimizing the impact on it, by making activities ​safe and sustainable​​

Ipsen Code of Conduct

Download

Transparency & Trust

Transparency and trust

Promoting the needs and rights of patients, employees and society at large is vital to us at Ipsen and it is exactly the objective and essence of our Corporate Social Responsibility Strategy. Our vision is to harness the power of our employees to have a responsible and sustainable impact on patients, society and the environment. We need to act with integrity, meaning that we must build relationships based on trust.

Transparency & Trust

Europe

EFPIA

In Europe, the European Federation of Pharmaceutical Industries and Associations (EFPIA) decreed the EFPIA Disclosure Code (June 2013), which requires the public disclosure of payments to HCPs and HCOs, starting in 2016 (for payments made in 2015).

 

Download the code
USA

Sunshine Act

In the USA, commercial interactions with HCPs are governed by the PhRMA Code on Interactions with Healthcare Professionals (2008). From a transparency perspective, the Patient Protection and Affordable Care Act (2010) (“Sunshine Act”) requires manufacturers to collect and track all financial relationships with physicians and teaching hospitals and to report this data to the Centers for Medicare and Medicaid Services (CMS).

Disclosure

Increasing transparency

The disclosures include transfers of value made for activities such as research and educational grants to HCOs as well as transfers of value to HCPs such as speaker fees, consultancy activities and participation in advisory boards.

Increasing transparency through the individual disclosure of transfers of value is good for all stakeholders, including HCPs, because it increases understanding of this important collaboration.

  Animal Welfare

Ipsen’s cell based assay adds approvals in the U.S. & Canada for its Botulinum Toxin

A customized training programme

As the cornerstone of our prevention program, awareness campaigns and training on environment, health and safety are regularly conducted. Each site has defined its training program according to its own risks and impacts. All employees are trained to recognize the inherent risks associated with their workplace and the environmental impact of their activities. These training programs meet our three commitments, formalized in the EHS Code of Conduct 3S:

Step up

Get personally involved

In your own safety and that of your colleagues and in the preservation of the environment. Consistently choose the safest way.

Speak out

Share your ideas and concerns

Regarding the environment, health and safety. Have the courage to discuss risk situations openly with others, even when they are beyond your scope of responsibility.

Stay safe

Look for ways to continuously improve

Our EHS performance. Report every “good catch” and “dangerous situations” so we can prevent future injury or environmental damage

Clinical trials and data sharing

Pharmaceutical companies are committed to enhancing public health through responsible sharing of clinical trial data in a manner that is consistent with the following principles: Safeguarding the privacy of patients Respecting the integrity of national regulatory systems Maintaining incentives for investment in biomedical research.

Clinical trials

Environment, Health & Safety

E.H.S

We are committed to fostering a culture of continuous improvement to maintain the highest environment, health and safety (EHS) standards and to stand out as a world-class partner and employer of choice.  We strive to integrate EHS excellence into our culture as we enable employees to deliver innovative products for patients worldwide. This starts with our S3 policy that helps us empower employees to ‘Step Up, Speak Out and Stay Safe’.  Applying an organized, methodical approach, we are able to promote awareness and dialogue at every level.

E.H.S

Corporate citizenship

Corporate citizenship

Initiatives

“Promoting the needs and rights of patients, employees and society at large is really important, and it is exactly the objective and essence of our Corporate Social Responsibility strategy: A human journey of shared commitments. Our vision is to harness the power of our employees to have a responsible and sustainable impact on patients, society and the environment.”

Dominique Laymand

Executive Vice-President, Chief Ethics and Compliance Officer

Corporate citizenship

Corporate Citizenship

Initiatives across the world

Ipsen invests in the wider global community focusing our efforts on patient associations and charitable work. Our commitment reflects our corporate social responsibility policy and we believe that our employees are our leading ambassadors.

Engaging with external scientific discovery

In collaboration with the American Association for the Advancement of Science, we launched the Bridging Biomedical Worlds conference series in 2014 to boost cooperation among researchers, clinicians and industry scientists.  The fourth edition took place in February 2018 in Singapore and explored ‘Genome Editing, the Next Frontier’ and the program covered revolutionary genome editing tools in various scientific fields, especially with respect to innovative therapies for cancer.

In a second event, developed in collaboration with the Karolinksa Institute, we examined how entrepreneurs can better serve patients through scientific innovation.  This event in March 2018 was open to the public and engaged politicians, leading scientists and the business community.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019